Ann Hematol

1. DE PAZ ARIAS R, Maortua Langdon G, Stuckey R, Giraldo P, et al
   Treatment-free remission after bosutinib discontinuation (BOSUTFR): results from a multicenter real-world study by the Spanish CML group.
   Ann Hematol. 2026;105:489.
   

   >> Share

   
   
2. CHEN G, Min C, Xu J, Zheng J, et al
   Successful treatment of B-cell acute lymphoblastic leukemia with SET-NUP214 rearrangement using venetoclax: A first case report and literature review.
   Ann Hematol. 2026;105:481.
   

   >> Share

   
   
3. IRIFUNE H, Semba Y, Uehara Y, Ohta T, et al
   Sequential emergence of FLT3-ITD and BCR::ABL1 during disease progression in relapsed acute myeloid leukemia.
   Ann Hematol. 2026;105:483.
   

   >> Share

   
   
4. LEE S, Kim HJ, Cheong JW, Shin HJ, et al
   Correction to: Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
   Ann Hematol. 2026;105:480.
   

   >> Share

   
   

   
   Blood

5. WENGE DV
   MEIS1 guardian USP22 fuels transcription in KMT2Ar leukemia.
   Blood. 2026;148:2212-2213.
   

   >> Share

   
   
6. LANE AA, Luskin MR, Keating J, LeBoeuf NR, et al
   Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm.
   Blood. 2026;148:2229-2238.
   

   >> Share

   
   

   
   BMC Cancer

7. DAI X, Zheng Y, Liu X, Huang R, et al
   IL-6/JAK2/STAT3 axis mediates non-classical monocyte-induced Th17-like conversion of activated Tregs in acute myeloid leukemia patients.
   BMC Cancer. 2026;26:1319.
   

   >> Share

   
   

   
   Bone Marrow Transplant

8. DUQUE-AFONSO J, Finke J, Ferhat AT, Galimard JE, et al
   Correction: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study
   Bone Marrow Transplant. 2026 Oct 23. doi: 10.1038/s41409-026-03073.
   

   >> Share

   
   

   
   Cancer Chemother Pharmacol

9. AVINENI M, Habo YK, Habo NK, Elsayed AAR, et al
   The role of tyrosine kinase inhibitors as a post-hematopoietic stem cell transplant continuation therapy for pediatric acute leukemia: a systematic review.
   Cancer Chemother Pharmacol. 2026;96:126.
   

   >> Share

   
   

   
   Cancer Lett

10. PEI X, Lv M, Zhao X, Liu Z, et al
    Rapid manufactured CAR-T cells enriched for CD45RA-negative T cells exhibit superior persistence compared to conventional CAR-T therapy.
    Cancer Lett. 2026;661:218865.
    

    >> Share

    
    

    
    Exp Hematol

11. SAFA-TAHAR-HENNI S, Milan T, DesCoteaux T, Roques E, et al
    Comparative analysis of KMT2A fusions in human models of acute myeloid leukemia.
    Exp Hematol. 2026 Oct 24:105955. doi: 10.1016/j.exphem.2026.105955.
    

    >> Share

    
    

    
    Int J Hematol

12. YAMAMORI A, Sajiki D, Tsumura Y, Hama A, et al
    Pediatric T-cell lymphoblastic lymphoma with t(9;17)(q34;q23)-associated N-terminally truncated NOTCH1 activation: a case report.
    Int J Hematol. 2026;124:747-751.
    

    >> Share

    
    
13. VIZCARDO P, Copaja-Corzo C, Untama J, Flores-Cohaila J, et al
    Incidence, etiology, and predictors of early mortality after induction chemotherapy for aml in a middle-income country.
    Int J Hematol. 2026;124:649-660.
    

    >> Share

    
    

    
    J Clin Oncol

14. GRUPP SA, Maude SL, Rives S, Hiramatsu H, et al
    Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL.
    J Clin Oncol. 2026;44:2999-3005.
    

    >> Share

    
    

    
    J Pediatr Hematol Oncol

15. YILMAZ KARAPINAR D, Karadas N, Gadashova A, Ortan G, et al
    Invasive Fungal Diseases in Pediatric Acute Lymphoblastic Leukemia Patients Receiving Mold-Active Primary Antifungal Prophylaxis.
    J Pediatr Hematol Oncol. 2026 Oct 30. doi: 10.1097/MPH.0000000000003312.
    

    >> Share

    
    
16. KAUL SA, Arora SK, Attri K, Hemal A, et al
    Oral Cryotherapy for Prevention of Oral Mucositis Following High-Dose Methotrexate in Children With Acute Lymphoblastic Leukemia: A Randomized Controlled Study.
    J Pediatr Hematol Oncol. 2026 Oct 28. doi: 10.1097/MPH.0000000000003315.
    

    >> Share

    
    

    
    Leuk Lymphoma

17. CHEUNG CYM, Halim NAA, Gan GG, Wang Y, et al
    The APLC 2025 consensus recommendations on the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Oct 30:1-19. doi: 10.1080/10428194.2026.2743349.
    

    >> Share

    
    
18. MARCINEK A, Schweneker K, Meggendorfer M, Haferlach T, et al
    Acute promyelocytic leukemia with clonal hematopoiesis: a case study of APL in complete molecular remission transitioning to MDS/MPN and its clinical implications.
    Leuk Lymphoma. 2026 Oct 30:1-3. doi: 10.1080/10428194.2026.2755196.
    

    >> Share

    
    
19. BANNATYNE J, Romon I, Dominguez JJ, Insunza A, et al
    Chronic myelomonocytic leukemia associated with lymphoid neoplasms.
    Leuk Lymphoma. 2026 Oct 30:1-5. doi: 10.1080/10428194.2026.2753811.
    

    >> Share

    
    
20. CHING LJ, Wang CH, Lo WL, Cheng YJ, et al
    Single-Cell RNA sequencing analysis of cellular heterogeneity and microenvironment-driven signaling networks in acute myeloid leukemia.
    Leuk Lymphoma. 2026 Oct 29:1-18. doi: 10.1080/10428194.2026.2740252.
    

    >> Share

    
    
21. ZEIDAN AM, Zhao R, Voegel A, Christensen D, et al
    Time burden and treatment patterns of patients with newly diagnosed acute myeloid leukemia receiving parenteral hypomethylating agents in combination with venetoclax.
    Leuk Lymphoma. 2026 Oct 28:1-10. doi: 10.1080/10428194.2026.2726604.
    

    >> Share

    
    
22. GJERTSEN BT, Isaksen MY, Ktoridou-Valen I, Azrakhsh NA, et al
    Metronomic per oral decitabine-cedazuridine plus venetoclax in acute myeloid leukemia.
    Leuk Lymphoma. 2026 Oct 28:1-5. doi: 10.1080/10428194.2026.2740250.
    

    >> Share

    
    
23. JIANG X, Zhang H, Miao Q, Wang Y, et al
    Secondary minimally differentiated acute leukemia with plasmacytoid dendritic cell differentiation (pDC-AML) following chemoradiotherapy for Ewing sarcoma in a child: biallelic EZH2 inactivation.
    Leuk Lymphoma. 2026 Oct 26:1-8. doi: 10.1080/10428194.2026.2751738.
    

    >> Share

    
    
24. MACLEOD S, Desmond R, Browne C, Fatima A, et al
    Hairy cell leukemia associated haemophagocytic lymphohistiocytosis.
    Leuk Lymphoma. 2026 Oct 23:1-3. doi: 10.1080/10428194.2026.2747549.
    

    >> Share

    
    

    
    Leuk Res

25. KARABULUT ZT, Hacibekiroglu T, Koseoglu FD, Senol Arslan BC, et al
    Real-world effectiveness and safety of fixed-duration frontline venetoclax-obinutuzumab for chronic lymphocytic leukemia: A nationwide multicenter retrospective cohort study.
    Leuk Res. 2026;171:108342.
    

    >> Share

    
    

    
    Leukemia

26. WANG Y, Li C, Gale RP, Wang W, et al
    Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.
    Leukemia. 2026 Oct 28. doi: 10.1038/s41375-026-03185.
    

    >> Share

    
    
27. HALILOVIC M, Abdelsalam M, Mieland AO, Neuroth S, et al
    Rapid proteasomal degradation of mutant feline McDonough sarcoma-like tyrosine kinase-3 overcomes inhibitor resistance mechanisms of acute myeloid leukemia cells.
    Leukemia. 2026 Oct 28. doi: 10.1038/s41375-026-03168.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share